Article -> Article Details
| Title | Latin America Mobile Payment Market Size, Growth, Share and Forecast Report 2025 |
|---|---|
| Category | Sciences --> Technology |
| Meta Keywords | Latin America Mobile Payment Market |
| Owner | Joey Moore |
| Description | |
| Market Overview The Europe gene therapy market size was valued at USD 2.5 Billion in 2024 and is expected to reach USD 7.3 Billion by 2033, growing at a CAGR of 12% during the forecast period 2025-2033. This growth is driven by advances in gene editing technologies, a rising prevalence of genetic disorders, increasing R&D investments, and favorable regulatory policies. Europe hosts over 250 ongoing clinical trials, positioning it as a key region in gene therapy development. Study Assumption Years
Europe Gene Therapy Market Key Takeaways
Sample Request Link: https://www.imarcgroup.com/Europe-Gene-Therapy-Market/requestsample Market Growth Factors The Europe gene therapy market is propelled by significant advancements in gene editing technologies such as CRISPR, which enable precise and safer gene modifications. Enhancements in viral vectors like adeno-associated viruses (AAV) and developments in non-viral delivery mechanisms are making gene therapies more scalable and clinically effective. Automation and digital technologies in manufacturing reduce costs and improve accessibility, broadening therapeutic possibilities across a range of genetic and acquired diseases. The rising prevalence of genetic disorders—such as hemophilia, spinal muscular atrophy, and inherited retinal disorders—and cancers like solid tumors and blood cancers, particularly in Italy and other European countries, are strong demand drivers. This growing disease burden expands the patient pool and encourages heightened investments from biotech firms, promoting faster therapy adoption across the region. Collaborations between biopharmaceutical companies, academic research institutions, and startups in Germany and other parts of Europe are accelerating the translation of innovations into market-ready treatments. Increased mergers and acquisitions facilitate pipeline expansion. Favorable regulatory frameworks and an increase in clinical trials, exceeding 250 in number, support a competitive environment fostering quicker approvals and broader patient access, further stimulating market growth. Market Segmentation
Regional Insights Europe is home to leading research institutions and over 250 ongoing clinical trials focused on cell and gene therapies. Germany, Italy, the United Kingdom, France, and Spain are key markets. The market is projected to grow at a CAGR of 12% from 2025 to 2033, with increasing investments and favorable regulatory environments fueling growth across these dominant regions. Recent Developments & News In May 2025, the EMA’s Committee for Medicinal Products for Human Use recommended conditional marketing authorization in the EU for Aucatzyl (obecabtagene autoleucel) to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults, receiving EU authorization in July 2025. In November 2024, Genethon announced plans to launch a Phase 3 trial of its Duchenne muscular dystrophy gene therapy, GNT0004, in Europe. Early data indicated improved motor function at higher doses. These developments highlight ongoing innovation and regulatory progress in the European gene therapy market. Key Players
About Us IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research. | |